Revenue remains highly volatile, fluctuating between $4.2M and $44.9M over the last ten quarters, while operating losses reached $57.5M in 2026Q1 due to an inability to leverage fixed R&D costs.
| Sales/Revenue | 79.21M | 75.13M | 28.83M | 38.02M | 485.42M | 375.2M | 233.16M | 11.61M | 8.83M |
| Revenue Growth % | 242.66% | 160.56% | -24.17% | -92.17% | 29.38% | 60.92% | 1907.88% | 31.49% | - |
| Cost of Goods Sold | 16.57M | 28.82M | 0 | 0 | 66.44M | 45.52M | 27.14M | 0 | 0 |
| COGS % of Revenue | - | 38.36% | - | - | 13.69% | 12.13% | 11.64% | - | - |
| Gross Profit | 62.63M | 46.31M | 28.83M | 38.02M | 418.99M | 329.69M | 206.01M | 11.61M | 8.83M |
| Gross Margin % | 79.07% | 61.64% | 100% | 100% | 86.31% | 87.87% | 88.36% | 100% | 100% |
| Gross Profit Growth % | - | 60.6% | -24.17% | -90.92% | 27.09% | 60.03% | 1674.13% | 31.49% | - |
| Operating Expenses | 274.6M | 263.41M | 343.6M | 275.23M | 202.48M | 125.27M | 49.98M | 15.73M | 9.58M |
| OpEx % of Revenue | - | 350.62% | 1191.69% | 723.82% | 41.71% | 33.39% | 21.44% | 135.45% | 108.53% |
| Selling, General & Admin | 72.88M | 76.58M | 85.49M | 75.18M | 66.75M | 48.76M | 15.75M | 4.01M | 2.86M |
| SG&A % of Revenue | - | 101.93% | 296.5% | 197.71% | 13.75% | 13% | 6.76% | 34.55% | 32.42% |
| Research & Development | 191M | 186.83M | 167.26M | 175.66M | 107.88M | 62.06M | 29.39M | 10.11M | 5.8M |
| R&D % of Revenue | - | 248.68% | 580.1% | 461.95% | 22.22% | 16.54% | 12.61% | 87.09% | 65.71% |
| Other Operating Expenses | 2M | 0 | 90.85M | 24.39M | 27.84M | 14.45M | 4.84M | 1.6M | 918K |
| Operating Income | -211.96M | -217.1M | -314.77M | -237.21M | 216.51M | 204.41M | 156.03M | -4.12M | -753K |
| Operating Margin % | -267.61% | -288.98% | -1091.69% | -623.82% | 44.6% | 54.48% | 66.92% | -35.45% | -8.53% |
| Operating Income Growth % | - | 31.03% | -32.7% | -209.56% | 5.92% | 31.01% | 3889.92% | -446.75% | - |
| EBITDA | -181.09M | -188.28M | -217.77M | -206.31M | 249.61M | 221.66M | 161.3M | -2.27M | 165K |
| EBITDA Margin % | -228.63% | -250.61% | -755.27% | -542.57% | 51.42% | 59.08% | 69.18% | -19.55% | 1.87% |
| EBITDA Growth % | 19.76% | 13.54% | -5.55% | -182.65% | 12.61% | 37.42% | 7205.81% | -1475.76% | - |
| D&A (Non-Cash Add-back) | 30.87M | 28.82M | 97M | 30.89M | 33.1M | 17.25M | 5.27M | 1.85M | 918K |
| EBIT | -205.54M | -217.1M | -301.15M | -223.05M | 227.06M | 221.9M | 164.34M | -2M | 521K |
| Net Interest Income | 23.92M | 28.33M | 38.47M | 42.25M | 12.03M | -1.9M | -6.22M | -54K | -170K |
| Interest Income | 23.92M | 28.33M | 38.47M | 42.25M | 16.08M | 3.33M | 293K | 155K | 42K |
| Interest Expense | 0 | 0 | 0 | 0 | 4.04M | 5.22M | 6.51M | 209K | 212K |
| Other Income/Expense | 37.82M | 39.51M | 114.37M | 63.18M | 22.59M | 14.74M | 1.8M | 1.91M | 1.06M |
| Pretax Income | -174.15M | -177.59M | -200.4M | -174.03M | 239.1M | 219.15M | 157.83M | -2.21M | 309K |
| Pretax Margin % | -219.86% | -236.39% | -695.02% | -457.67% | 49.26% | 58.41% | 67.69% | -19.04% | 3.5% |
| Income Tax | -30.19M | -31.18M | -37.54M | -27.63M | 80.58M | 65.69M | 38.91M | 0 | 0 |
| Effective Tax Rate % | 17.34% | 17.56% | 18.73% | 15.88% | 33.7% | 29.97% | 24.66% | 0% | 0% |
| Net Income | -143.96M | -146.41M | -162.86M | -146.4M | 158.52M | 153.46M | 118.92M | -2.21M | 309K |
| Net Margin % | -181.75% | -194.88% | -564.83% | -385% | 32.66% | 40.9% | 51% | -19.04% | 3.5% |
| Net Income Growth % | 14.24% | 10.1% | -11.24% | -192.35% | 3.29% | 29.05% | 5478.47% | -815.53% | - |
| Net Income (Continuing) | -143.96M | -146.41M | -162.86M | -146.4M | 158.52M | 153.46M | 118.92M | -2.21M | 309K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.48 | -0.49 | -0.55 | -0.51 | 0.50 | 0.48 | 0.45 | -0.01 | 0.00 |
| EPS Growth % | 15.79% | 10.91% | -7.84% | -202% | 4.17% | 6.67% | 4468.93% | - | - |
| EPS (Basic) | - | -0.49 | -0.55 | -0.51 | 0.56 | 0.56 | 0.32 | -0.01 | 0.00 |
| Diluted Shares Outstanding | 303.07M | 298.71M | 294.33M | 289.17M | 314.83M | 318.29M | 263.13M | 237.72M | 151.04M |
| Basic Shares Outstanding | 303.07M | 298.71M | 294.33M | 289.17M | 285.06M | 275.76M | 267.82M | 215.41M | 151.06M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
High cash burn rate
As reported in financial statements, ABCL's revenue trajectory remains highly erratic, with quarterly figures fluctuating between $4.2M and $44.9M over the last ten periods, suggesting that the company's reliance on lumpy milestone payments prevents the establishment of a predictable, sustainable organic growth baseline for investors.
The extreme variance in top-line performance highlights the difficulty in assessing the company's true commercial momentum outside of sporadic milestone recognition. Investors should monitor whether the firm can transition toward more consistent, recurring revenue streams, as the current reliance on binary clinical events creates significant forecasting uncertainty.
Based on AbCellera's reported figures, gross margins have demonstrated extreme volatility, swinging from a negative 4.1% in 2026Q1 to a perfect 100% in several prior quarters, which indicates that the cost of revenue is highly sensitive to the specific nature of active lab-based discovery projects.
The structural shift toward internal lab work appears to be eroding the high-margin profile previously enjoyed during periods of passive royalty collection. This suggests that the company's move toward a more capital-intensive discovery model may permanently compress gross margins compared to its earlier, more asset-light service phase.
According to recent SEC filings, ABCL's operating expenses, particularly R&D, consistently outpace gross profit, resulting in persistent operating losses that reached $57.5M in 2026Q1, suggesting that the company has yet to achieve the necessary scale to leverage its fixed infrastructure against its current revenue base.
The persistent gap between R&D investment and revenue generation implies that the platform's technical development costs are not yet being offset by commercial success. Without a significant increase in royalty-generating programs, the current operating structure appears to be a drag on long-term profitability, necessitating careful scrutiny of future expense discipline.
As detailed in historical income statements, AbCellera maintains a heavy fixed-cost structure, with R&D spending frequently exceeding $40M per quarter, which highlights the significant capital requirements needed to sustain its proprietary microfluidic and computational platform in a highly competitive and resource-intensive biotechnology discovery environment.
The company's commitment to maintaining sophisticated infrastructure suggests a high break-even threshold that is currently not being met by its discovery services. This cost structure warrants further investigation into whether management can optimize its R&D spend without compromising the platform's competitive edge in antibody discovery.
Based on the provided financial data, the company's inability to generate positive net income across the observed ten-quarter period raises questions regarding the long-term viability of its current discovery-as-a-service model, particularly as cash reserves appear to be depleting in the face of ongoing operational losses.
Short-sellers may focus on the widening gap between cash burn and revenue, arguing that the platform's value proposition has not been sufficiently validated by commercial outcomes. The transition toward internal pipeline development may be viewed as a defensive pivot rather than a strategic expansion, potentially increasing the risk profile for shareholders.
Quick answers to the most common questions about buying ABCL stock.
For fiscal year 2025, AbCellera Biologics Inc. (ABCL) reported total revenue of $75.1M. This represents a 750.7% increase compared to $8.8M in 2018.
AbCellera Biologics Inc. (ABCL) reported a net loss of $146.4M for the fiscal year ending 2025.
AbCellera Biologics Inc. (ABCL) reported an operating income of $-217.1M, resulting in an operating profit margin of -289.0%. This margin reflects the operational efficiency of the business before interest and taxes.
AbCellera Biologics Inc. (ABCL) generated $46.3M in gross profit for the year, representing a gross profit margin of 61.6%. This demonstrates the company's core pricing power and production efficiency.